FDA celebrates 50th biosimilar approval as it releases new Action Plan

On April 25, the US Food and Drug Administration (FDA) approved the 50th biosimilar for marketing in the USA.

Since the FDA’s biosimilars program started, the agency has contributed to the growth of biosimilar adoption and the increasing availability of therapeutic options for patients who face increasing costs and restrictions to access much needed medications.

The FDA has approved biosimilars to treat a wide range of conditions such as diabetes, skin conditions, bowel disorders, osteoporosis, arthritis, macular degeneration, cancer and more. These treatment options can give patients access to life-saving or life-sustaining treatment at potentially reduced costs.